DDrare: Database of Drug Development for Rare Diseases

167. マルファン症候群
［臨床試験数：19，薬物数：38（DrugBank：10），標的遺伝子数：10，標的パスウェイ数：49］

Searched query = "Marfan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ATENOLOL; Aliskiren; Aprovel; Atenolol; Atenolol or Propranolol; BLOKIUM 50 mg comprimidos; Blokium 50; COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula; Coozar; Coversyl; Coversyl (perindopril); Cozaar; Cozaar 50; Doxycycline; Doxycycline 100-200mg capsules daily for 6 months; Doxycycline Hyclate Ph.Eur; Irbesartan; Irbesartan 150-300mg capsules daily for 6 months; LOBIVON*28CPR 5MG; LORTAAN*28CPR RIV DIV 50MG; LOSARTAN POTASSIUM; Lobivon; Lortaan; Losartan; Losartan Potassium; Losartan and Atenolol or Propranolol; Losartan and nebivolol; Losartan potassium; Nebivolol; PERINDOPRIL; Perindopril; Potassium; Propranolol; VERAPAMIL; Verapamil; Verapamil SR; Vibrox; Vibrox 100mg Capsules

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-001462-81-IT (EUCTR)	27/10/2008	17/03/2008	Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND	Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND	Marfan Syndrome MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome	Trade Name: LORTAAN 28CPR RIV DIV 50MG INN or Proposed INN: Losartan Trade Name: LOBIVON 28CPR 5MG INN or Proposed INN: Nebivolol	OSPEDALE POLICLINICO S. MATTEO	NULL	Not Recruiting			Female: yes Male: yes		Phase 3	Italy
2	NCT00683124 (ClinicalTrials.gov)	July 2008	21/5/2008	Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients	Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.	Marfan Syndrome	Drug: Losartan and nebivolol;Drug: Losartan;Drug: Nebivolol	IRCCS Policlinico S. Matteo	Merck Sharp & Dohme Corp.;Menarini Group	Recruiting	12 Months	55 Years	Both	291	Phase 3	Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2008-001462-81-IT
(EUCTR)

27/10/2008

17/03/2008

Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND

Marfan Syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome

Trade Name: LORTAAN *28CPR RIV DIV 50MG
INN or Proposed INN: Losartan
Trade Name: LOBIVON *28CPR 5MG
INN or Proposed INN: Nebivolol

OSPEDALE POLICLINICO S. MATTEO

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

Italy

NCT00683124
(ClinicalTrials.gov)

July 2008

21/5/2008

Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients

Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.

Marfan Syndrome

Drug: Losartan and nebivolol;Drug: Losartan;Drug: Nebivolol

IRCCS Policlinico S. Matteo

Merck Sharp & Dohme Corp.;Menarini Group

Recruiting

12 Months

55 Years

Both

291

Phase 3

Italy